Silexion Therapeutics Corp (SLXN) Form 8-K — Aug 21, 2026

$SLXNForm 8-KItems 3.01Filed Aug 21, 2026, 4:21 PM ET0001178913-26-004223Original filing

Silexion Therapeutics Corp (SLXN) received a Nasdaq delisting notice on August 18, 2026 for non-compliance with the minimum $2,500,000 shareholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market. The deficiency is severe: the company's Form 10-Q for the quarter ended June 30, 2026 reported shareholders' equity of just $44,000, and net losses incurred after quarter-end pushed the company further below the threshold despite a prior belief that compliance had been restored on a pro forma basis.

Key figures

Nasdaq Rule: 5550(b)(1)
Appeal Deadline: August 25, 2026
Mandatory Panel Monitor Since: September 23, 2025
Shareholders Equity As Of June30 2026: $44,000
Minimum Shareholders Equity Requirement: $2,500,000

Price after filing

1 day: 0.0%7 days: -8.6%30 days: +10.5%

Close on the filing date to close N calendar days later (from $0.39). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.